Andres Y. Maldonado
Stock Analyst at HC Wainwright & Co.
(4.72)
# 118
Out of 5,169 analysts
48
Total ratings
58.7%
Success rate
54.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andres Y. Maldonado
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBP NovaBridge Biosciences | Reiterates: Buy | $9 | $2.81 | +220.28% | 2 | Mar 16, 2026 | |
| ERAS Erasca | Maintains: Buy | $15 → $20 | $13.82 | +44.72% | 3 | Mar 13, 2026 | |
| FHTX Foghorn Therapeutics | Reiterates: Buy | $13 | $4.86 | +167.49% | 1 | Mar 10, 2026 | |
| DAWN Day One Biopharmaceuticals | Downgrades: Neutral | $22 → $22 | $21.32 | +0.87% | 3 | Mar 10, 2026 | |
| ENGN enGene Holdings | Reiterates: Buy | $25 | $7.26 | +244.35% | 3 | Mar 9, 2026 | |
| SRRK Scholar Rock Holding | Reiterates: Buy | $58 | $40.25 | +44.10% | 3 | Mar 3, 2026 | |
| CGON CG Oncology | Maintains: Buy | $75 → $80 | $65.10 | +22.89% | 5 | Feb 27, 2026 | |
| IBRX ImmunityBio | Maintains: Buy | $10 → $15 | $8.67 | +73.01% | 9 | Feb 23, 2026 | |
| IMNM Immunome | Initiates: Buy | $40 | $20.85 | +91.85% | 1 | Feb 12, 2026 | |
| TARA Protara Therapeutics | Reiterates: Buy | $23 | $5.34 | +330.71% | 3 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $18 | $5.57 | +223.16% | 1 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2 → $10 | $21.70 | -53.92% | 1 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $4 | $0.83 | +379.50% | 1 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $60 | $46.13 | +30.07% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $7 | $1.09 | +542.20% | 1 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $23.95 | +67.01% | 2 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $9.28 | +331.27% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $5.13 | +348.34% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $105 | $58.70 | +78.88% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $22 | $6.63 | +231.83% | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $20 | $10.96 | +82.57% | 1 | Aug 8, 2025 |
NovaBridge Biosciences
Mar 16, 2026
Reiterates: Buy
Price Target: $9
Current: $2.81
Upside: +220.28%
Erasca
Mar 13, 2026
Maintains: Buy
Price Target: $15 → $20
Current: $13.82
Upside: +44.72%
Foghorn Therapeutics
Mar 10, 2026
Reiterates: Buy
Price Target: $13
Current: $4.86
Upside: +167.49%
Day One Biopharmaceuticals
Mar 10, 2026
Downgrades: Neutral
Price Target: $22 → $22
Current: $21.32
Upside: +0.87%
enGene Holdings
Mar 9, 2026
Reiterates: Buy
Price Target: $25
Current: $7.26
Upside: +244.35%
Scholar Rock Holding
Mar 3, 2026
Reiterates: Buy
Price Target: $58
Current: $40.25
Upside: +44.10%
CG Oncology
Feb 27, 2026
Maintains: Buy
Price Target: $75 → $80
Current: $65.10
Upside: +22.89%
ImmunityBio
Feb 23, 2026
Maintains: Buy
Price Target: $10 → $15
Current: $8.67
Upside: +73.01%
Immunome
Feb 12, 2026
Initiates: Buy
Price Target: $40
Current: $20.85
Upside: +91.85%
Protara Therapeutics
Feb 10, 2026
Reiterates: Buy
Price Target: $23
Current: $5.34
Upside: +330.71%
Feb 4, 2026
Assumes: Buy
Price Target: $18
Current: $5.57
Upside: +223.16%
Dec 22, 2025
Maintains: Neutral
Price Target: $2 → $10
Current: $21.70
Upside: -53.92%
Dec 19, 2025
Maintains: Buy
Price Target: $10 → $4
Current: $0.83
Upside: +379.50%
Dec 9, 2025
Maintains: Buy
Price Target: $20 → $60
Current: $46.13
Upside: +30.07%
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.09
Upside: +542.20%
Oct 27, 2025
Reiterates: Buy
Price Target: $40
Current: $23.95
Upside: +67.01%
Oct 20, 2025
Reiterates: Buy
Price Target: $40
Current: $9.28
Upside: +331.27%
Sep 29, 2025
Reiterates: Buy
Price Target: $23
Current: $5.13
Upside: +348.34%
Sep 29, 2025
Maintains: Buy
Price Target: $70 → $105
Current: $58.70
Upside: +78.88%
Aug 13, 2025
Reiterates: Buy
Price Target: $22
Current: $6.63
Upside: +231.83%
Aug 8, 2025
Maintains: Buy
Price Target: $25 → $20
Current: $10.96
Upside: +82.57%